An Open-label, Dose-escalation Phase Ia Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SM3321 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 21 Dec 2023
At a glance
- Drugs SM-3321 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Beijing StarMab BioMed Technology
Most Recent Events
- 23 Oct 2023 New trial record